Edition:
United States

Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

5.37USD
24 May 2017
Change (% chg)

-- (--)
Prev Close
$5.37
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
155,381
52-wk High
$9.40
52-wk Low
$1.47

CNAT.OQ

Chart for CNAT.OQ

About

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $156.82
Shares Outstanding(Mil.): 29.20
Dividend: --
Yield (%): --

Financials

  CNAT.OQ Industry Sector
P/E (TTM): -- 141.11 17.36
EPS (TTM): -1.10 -- --
ROI: -63.61 2.25 -5.72
ROE: -102.67 0.17 -5.10

BRIEF-Conatus prices offering of 5.20 mln shares at $5.50/shr

* Conatus announces pricing of public offering of common stock

May 11 2017

Novartis exercises option with Conatus for NASH product

ZURICH Novartis is exercising its option with Conatus Pharmaceuticals for an exclusive license for the global development and commercialization of emricasan for treating liver disease NASH, the Swiss drugmaker said.

May 04 2017

BRIEF-Conatus Pharmaceuticals Q1 revenue $7.0 million

* Conatus Pharmaceuticals reports first quarter 2017 financial results and program updates

May 04 2017

Novartis exercises option with Conatus for NASH product

ZURICH, May 4 Novartis is exercising its option with Conatus Pharmaceuticals for an exclusive license for the global development and commercialization of emricasan for treating liver disease NASH, the Swiss drugmaker said.

May 04 2017

BRIEF-Conatus Pharmaceuticals says appointed Steven Mento as acting principal financial officer on March 16

* Conatus Pharmaceuticals Inc - on March 16, board appointed Steven Mento as company's acting principal financial officer Source text: (http://bit.ly/2mN9zSd) Further company coverage:

Mar 21 2017

BRIEF-Conatus Pharma qtrly loss per share $0.35

* Conatus pharmaceuticals reports 2016 financial results and program updates

Mar 15 2017

BRIEF-Conatus Pharmaceuticals says cfo Charles Cashion resigned

* On February 16, 2017, Charles J. Cashion tendered his resignation as chief financial officer Source text- http://bit.ly/2lfEBmE Further company coverage:

Feb 17 2017

BRIEF-Conatus Pharmaceuticals issued a convertible promissory note of $15 mln to Novartis Pharma AG pursuant to investment agreement entered in Dec 2016

* Conatus Pharmaceuticals - On Feb 15, co issued a convertible promissory note of $15 million to Novartis Pharma AG pursuant to investment agreement entered in Dec 2016 Source text: [http://bit.ly/2lpeTOz] Further company coverage:

Feb 16 2017

BRIEF-Conatus Pharmaceuticals promotes Daniel Ripley to senior vice president

* Conatus Pharmaceuticals promotes Daniel L. Ripley to senior vice president, business development, program and alliance management Source text for Eikon: Further company coverage:

Feb 02 2017

Conatus to receive $50 million in liver drug deal with Novartis

Swiss drugmaker Novartis on Monday said it signed a licensing deal to co-develop a fatty liver disease drug with Conatus Pharmaceuticals Inc, under which the small U.S. company will receive $50 million up front.

Dec 19 2016

More From Around the Web

Competitors

  Price Chg
BASF SE (BASFn.DE) €84.70 +0.10
Johnson & Johnson (JNJ.N) $127.51 -0.01
Novartis AG (NOVN.S) CHF79.10 +0.05
Merck & Co., Inc. (MRK.N) $64.93 +0.38
Roche Holding Ltd. (ROG.S) CHF267.20 -0.70
Roche Holding Ltd. (RO.S) CHF267.50 +0.25

Earnings vs. Estimates